Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C

Hepatology Research

Volumn 44, Issue 12, 2014, Pages 1165-1171

  Fukuda, Kazuto ^a   Imai, Yasuharu ^a   Hiramatsu, Naoki ^b   Irishio, Keiko ^a   Igura, Takumi ^a   Sawai, Yoshiyuki ^a   Kogita, Sachiyo ^a   Makino, Yuki ^a   Mizumoto, Rui ^a   Matsumoto, Yasushi ^a   Nakahara, Masanori ^a   Zushi, Sinichiro ^a   Kajiwara, Nobuyuki ^a   Oze, Tsugiko ^b   Kawata, Sumio ^c   Hayashi, Norio ^d   Takehara, Tetsuo ^b  

^a IKEDA MUNICIPAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Hyogo Prefectural Nishinomiya Hospital   (Japan)

^d KANSAI ROSAI HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Peginterferon; Renal impairment; Ribavirin; Telaprevir

Indexed keywords

CREATININE; CYSTATIN C; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; INTERLEUKIN 28B; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; URINE VOLUME; VIRUS LOAD;

EID: 84914099484     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12229     Document Type: Article

References (22)

1. Hoofnagle JH. Course and outocome of hepatitis C. Hepatology 2002; 36: S21-9.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46.
3. Kasahara A, Tanaka H, Okanoue T et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004; 11: 148- 56.
4. Imai Y, Kawata S, Tamura S et al. Relationship of interferon therapy and hepatocellular carcinoma in patients with chronic heaptitis C. Ann Intern Med 1998; 129: 94-9.
5. Jacobson JM, NcHutchinson JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
6. Zeuzem S, Andreone P, Pol S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
7. Sherman KE, Flamm SL, Afdhal NH et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
8. Kumada H, Toyota J, Okanoue T, Chayama K, Tsubouchi H, Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012; 56: 78-84.
9. Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H. Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. J Viral Hepat 2012; 19: e134- e42.
10. Yamada I, Suzuki F, Kamiya N et al. Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection. J Viral Hepat 2012; 19: e112-19.
11. Toyota J, Ozeki I, Karino Y et al. Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b. J Viral Hepat 2013; 20: 167-73.
12. Suzuki F, Suzuki Y, Sezaki H et al. Exploratory study on telaprevir given every 8h at 500mg or 750mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients. Hepatol Res 2013; 43: 691-701.
13. Chobanian AV, Bakris GL, Black HR et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
14. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36 (Suppl 1): S4.
15. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
16. Suzuki F, Suzuki Y, Akuta N et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011; 53: 415-21.
17. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genomewide association studies. J Hum Genet 2001; 46: 471-7.
18. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
19. Akuta N, Suzuki F, Kawamura Y et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46: 403-10.
20. Kakuda H, Kanasaki K, Koya D, Takekoshi N. The administration of pitavastatin augments creatinine clearance associated with reduction in oxidative stress parameters: acute and early events. Clin Exp Nephrol 2013; 17: 240-47.
21. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-8.
22. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012; 84: 1096-102.